Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Could Drug Price Spikes Spur ANDA Priority Reviews?

This article was originally published in The Pink Sheet Daily

Executive Summary

Sens. Collins and Warren want FDA to have economic trigger to speed generics; CDER's Woodcock says it's possible but needs clear legislative definition.


Related Content

FDA's Next Commissioner: Will Trump Follow Hamburg Or McClellan 'Schedule'?
Trump Takes Office, Change At US FDA Arrives With ‘Beachhead Teams’
ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?
Mylan Joins Firms Facing DOJ Probe On Price Hikes; Senate Plans Industry-Free Hearing


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst